Abstract
The role of dopamine in sleep-wake regulation is considered as a wakefulness-promoting agent. For the clinical treatment of excessive daytime sleepiness, drugs have been commonly used to increase dopamine release. However, sleep disorders or lack of sleep are related to several dopaminerelated disorders. The effects of dopaminergic agents, nevertheless, are mediated by two families of dopamine receptors, D1 and D2-like receptors; the first family increases adenylyl cyclase activity and the second inhibits adenylyl cyclase. For this reason, the dopaminergic agonist effects on sleep-wake cycle are complex. Here, we review the state-of-the-art and discuss the different effects of dopaminergic agonists in sleep-wake states, and propose that these receptors account for the affinity, although not the specificity, of several effects on the sleep-wake cycle.
Keywords: Dopamine, dopamine agonist, sleep-wake states, wakefulness-promoting agents, receptors, nuclei.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Dopaminergic Modulation of Sleep-Wake States
Volume: 16 Issue: 4
Author(s): Andrea Herrera-Solis, Wendy Herrera-Morales, Luis Nunez-Jaramillo and Oscar Arias-Carrion*
Affiliation:
- Unidad de Trastornos del Movimiento y Sueño (TMS). Hospital General Dr. Manuel Gea González, Avenida Calzada de Tlalpan 4800, Tlalpan, Sección XVI, Ciudad de México, C.P. 14080,Mexico
Keywords: Dopamine, dopamine agonist, sleep-wake states, wakefulness-promoting agents, receptors, nuclei.
Abstract: The role of dopamine in sleep-wake regulation is considered as a wakefulness-promoting agent. For the clinical treatment of excessive daytime sleepiness, drugs have been commonly used to increase dopamine release. However, sleep disorders or lack of sleep are related to several dopaminerelated disorders. The effects of dopaminergic agents, nevertheless, are mediated by two families of dopamine receptors, D1 and D2-like receptors; the first family increases adenylyl cyclase activity and the second inhibits adenylyl cyclase. For this reason, the dopaminergic agonist effects on sleep-wake cycle are complex. Here, we review the state-of-the-art and discuss the different effects of dopaminergic agonists in sleep-wake states, and propose that these receptors account for the affinity, although not the specificity, of several effects on the sleep-wake cycle.
Export Options
About this article
Cite this article as:
Herrera-Solis Andrea, Herrera-Morales Wendy , Nunez-Jaramillo Luis and Arias-Carrion Oscar *, Dopaminergic Modulation of Sleep-Wake States, CNS & Neurological Disorders - Drug Targets 2017; 16 (4) . https://dx.doi.org/10.2174/1871527316666170320145429
DOI https://dx.doi.org/10.2174/1871527316666170320145429 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuropathic Pain: Models and Mechanisms
Current Pharmaceutical Design Mitochondrial-Associated Metabolic Changes and Neurodegeneration in Huntingtons Disease - from Clinical Features to the Bench
Current Drug Targets Synthesis and Anticonvulsant Activity of 3-(alkylamino, alkoxy)-1,3,4,5- Tetrahydro-2H-benzo [b] azepine-2-one Derivatives
CNS & Neurological Disorders - Drug Targets Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme
Current Pharmaceutical Design Anxiety: A Systematic Review of Neurobiology, Traditional Pharmaceuticals and Novel Alternatives from Medicinal Plants
CNS & Neurological Disorders - Drug Targets Antiviral Herbs - Present and Future
Infectious Disorders - Drug Targets Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety
Current Molecular Pharmacology GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer’s Disease Patients
Current Alzheimer Research Testosterone Replacement Therapy in Older Male Subjective Memory Complainers: Double-Blind Randomized Crossover Placebo-Controlled Clinical Trial of Physiological Assessment and Safety
CNS & Neurological Disorders - Drug Targets The Hyperactive Rat: An Animal Model for Bipolar Disorder
Current Psychiatry Reviews NGF-Cholinergic Dependency in Brain Aging, MCI and Alzheimers Disease
Current Alzheimer Research Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Synthesis and Pharmacological Studies of Novel 3-Substituted Indole Derivatives as Potential Anti-Inflammatory and Analgesic Agents
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Nitric Oxide Related Therapeutic Phenomenon: A Challenging Task
Current Pharmaceutical Design Effects of Mindfulness on Diabetes Mellitus: Rationale and Overview
Current Diabetes Reviews Euglycemic Diabetic Ketoacidosis: A Review
Current Diabetes Reviews Editorial [Hot Topic:New Approaches for the Treatment of Pain and Inflammation (Guest Editor: Kaustav Biswas)]
Current Topics in Medicinal Chemistry Recent Advances and Novel Approaches for Nose to Brain Drug Delivery for Treatment of Migraine
Drug Delivery Letters Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier
Current Drug Metabolism New Targets for Therapy in Polyglutamine (polyQ) Expansion Diseases
Current Drug Therapy